Loading
Iza-bren / Adagrasib / Non Small Cell Lung Cancer · Phase 1 Trial
ClinicalTrials.gov · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 safety and tolerability study of izalontamab brengitecan combined with adagrasib in patients with advanced KRAS G12C-mutant NSCLC resistant to prior KRAS inhibitor therapy. The trial is actively recruiting; no results are yet available in this registry record.
Phase 1, Interventional, Single Group, Open label, Treatment purpose. Non-small Cell Lung Cancer; age from 18 Years. Intervention: Combo Treatment with Izalontamab Brengitecan (IV) + Adagras…. n = 18. 1 site: United States.
This is a Phase 1 safety and tolerability study of izalontamab brengitecan combined with adagrasib in patients with advanced KRAS G12C-mutant NSCLC resistant to prior KRAS inhibitor therapy. The trial is actively recruiting; no results are yet available in this registry record.
Registry record only; no efficacy or safety results are reported.
This early-phase trial offers no clinical guidance at present. Clinicians should await Phase 1 safety results and subsequent efficacy studies before considering this combination outside a clinical trial setting.
Phase 1 study of a novel drug combination in advanced NSCLC; registry record with no results posted; designed to evaluate safety in a small population.
As stated by the source record.
Quoted from the source exactly as published.
This early-phase trial offers no clinical guidance at present. Clinicians should await Phase 1 safety results and subsequent efficacy studies before considering this combination outside a clinical trial setting.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07382726). This is a study registration, not published results. Lead sponsor: M.D. Anderson Cancer Center. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 18 participants (ESTIMATED). Conditions: Non-small Cell Lung Cancer. Interventions: DRUG: Adagrasib; DRUG: Iza-bren. Primary outcome measures: Safety and Adverse Events (AEs) , Through study completion; an average of 1 year. Brief summary: This research is being done to test a combination of two drugs, Izalontamab Brengitecan (iza-bren) and Adagrasib, in patients with advanced KRAS G12C-mutant NSCLC that hasn't responded to other treatments. The purpose is to see if this combination works better than existing treatments for people whose cancer keeps growing despite KRAS G12C inhibitors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.